Immunovant (IMVT) Non-Current Assets (2018 - 2026)
Immunovant's (IMVT) quarterly Non-Current Assets came in at $8.2 million in Q1 2026, down 4.26% YoY from $8.6 million in Q1 2025, and down 13.31% on a QoQ basis from $9.5 million in Q4 2025.
Immunovant (IMVT) Non-Current Assets (2018 - 2026) Analysis & Trends
Immunovant (IMVT) has 9 years of Non-Current Assets data on file, last reported at $8.2 million in Q1 2026.
- Quarterly Non-Current Assets fell 4.26% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $36.7 million (up 41.75% YoY) and the FY2026 annual result came in at $8.2 million, down 4.26% from the prior year.
- Non-Current Assets eased to $8.2 million in Q1 2026, from $9.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $9.7 million in Q2 2025 to a low of $595000.0 in Q1 2024.
- A 5-year average of $4.5 million and a median of $2.4 million in 2022 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets tumbled 63.21% — and 2025, when it soared 1433.6%.
- Tracing IMVT's Non-Current Assets over 5 years: stood at $1.8 million in 2022, then plunged by 63.21% to $670000.0 in 2023, then jumped by 1152.39% to $8.4 million in 2024, then rose by 12.66% to $9.5 million in 2025, then slipped by 13.31% to $8.2 million in 2026.
- The last three Non-Current Assets figures came in at $8.2 million (Q1 2026), $9.5 million (Q4 2025), and $9.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Immunovant | 8.63 Bn | 7.83 Bn | - | 1.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Mn |
| Mar 31, 2026 | 8.20 Mn |
| Dec 31, 2025 | 9.45 Mn |
| Sep 30, 2025 | 9.41 Mn |
| Jun 30, 2025 | 9.68 Mn |
| Mar 31, 2025 | 8.56 Mn |
| Dec 31, 2024 | 8.39 Mn |
| Sep 30, 2024 | 8.34 Mn |
| Jun 30, 2024 | 631,000.00 |
| Mar 31, 2024 | 595,000.00 |
| Dec 31, 2023 | 670,000.00 |
| Sep 30, 2023 | 893,000.00 |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 1.51 Mn |
| Dec 31, 2022 | 1.82 Mn |
| Sep 30, 2022 | 2.06 Mn |
| Jun 30, 2022 | 2.35 Mn |
| Mar 31, 2022 | 2.63 Mn |
| Dec 31, 2021 | 2.70 Mn |
| Sep 30, 2021 | 2.94 Mn |